

Nicola Nicolai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5132962/publications.pdf>

Version: 2024-02-01

122
papers

5,931
citations

101543

36
h-index

76900

74
g-index

128
all docs

128
docs citations

128
times ranked

5023
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines on Testicular Cancer: 2015 Update. <i>European Urology</i> , 2015, 68, 1054-1068.	1.9	538
2	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	1.9	488
3	European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCCG). <i>Annals of Oncology</i> , 2004, 15, 1377-1399.	1.2	441
4	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4906-4911.	1.6	267
5	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	1.9	243
6	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, 1658-1686.	1.2	228
7	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	1.9	195
8	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
9	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 810-816.	10.7	130
10	Taxanes in Combination with Cisplatin and Fluorouracil for Advanced Penile Cancer: Preliminary Results. <i>European Urology</i> , 2009, 55, 546-551.	1.9	127
11	Penoscopically Controlled CO2 Laser Excision for Conservative Treatment of In Situ and T1 Penile Carcinoma: Report on 224 Patients. <i>European Urology</i> , 2008, 54, 875-884.	1.9	115
12	A Surveillance Study of Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: 10-Year Followup. <i>Journal of Urology</i> , 1995, 154, 1045-1049.	0.4	106
13	Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. <i>BJU International</i> , 2011, 107, 28-39.	2.5	83
14	Survival of male genital cancers (prostate, testis and penis) in Europe 1999â€“2007: Results from the EURO CARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2206-2216.	2.8	82
15	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. <i>European Urology</i> , 2013, 64, 30-36.	1.9	81
16	Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. <i>European Urology</i> , 2018, 73, 394-405.	1.9	78
17	Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v140-v146.	1.2	76
18	Adjuvant chemotherapy is associated with improved overall survival in pelvic nodeâ€“positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 496.e17-496.e23.	1.6	76

#	ARTICLE	IF	CITATIONS
19	The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. <i>Journal of Urology</i> , 2014, 191, 977-982.	0.4	75
20	Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v147-v154.	1.2	74
21	Proof of Activity of Anti-“Epidermal Growth Factor Receptor” Targeted Therapy for Relapsed Squamous Cell Carcinoma of the Penis. <i>Journal of Clinical Oncology</i> , 2011, 29, e650-e652.	1.6	74
22	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	1.2	71
23	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016, 196, 95-100.	0.4	70
24	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	2.5	70
25	A Simple Model for Predicting Nodal Metastasis in Patients With Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors Undergoing Retroperitoneal Lymph Node Dissection Only. <i>Journal of Urology</i> , 2004, 171, 172-176.	0.4	69
26	Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation. <i>International Journal of Surgical Pathology</i> , 2011, 19, 321-327.	0.8	66
27	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 323-330.	1.9	59
28	Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. <i>BJU International</i> , 2011, 107, 1088-1094.	2.5	54
29	Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. <i>European Urology</i> , 2018, 73, 899-907.	1.9	51
30	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β^2 (TGF β^2) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	2.6	50
31	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	10.7	48
32	Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>European Urology</i> , 2010, 58, 912-918.	1.9	47
33	The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. <i>BJU International</i> , 2012, 110, 998-1003.	2.5	47
34	Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. <i>Urology</i> , 2015, 85, 402-406.	1.0	47
35	Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 605.e17-605.e23.	1.6	39
36	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	1.9	38

#	ARTICLE	IF	CITATIONS
37	Comparison between Clinical and Pathological Staging in Low Stage Nonseminomatous Germ Cell Testicular Tumors. <i>Journal of Urology</i> , 1992, 148, 76-79.	0.4	37
38	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. <i>European Journal of Cancer</i> , 2012, 48, 159-169.	2.8	37
39	Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. <i>Journal of Urology</i> , 2015, 194, 696-702.	0.4	37
40	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
41	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.4	36
42	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. <i>BJU International</i> , 2009, 104, 340-346.	2.5	34
43	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017, 28, 1346-1351.	1.2	34
44	Extent of pelvic lymph node dissection in penile cancer may impact survival. <i>World Journal of Urology</i> , 2016, 34, 353-359.	2.2	32
45	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 518-523.	1.9	28
46	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 63-69.e1.	1.9	27
47	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	1.9	27
48	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	1.9	27
49	A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 306-312.e3.	1.9	25
50	Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. <i>European Urology Focus</i> , 2019, 5, 737-741.	3.1	25
51	Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. <i>Annals of Oncology</i> , 1992, 3, 211-216.	1.2	24
52	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	1.9	24
53	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. <i>BJU International</i> , 2015, 116, 727-733.	2.5	23
54	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 261-264.e4.	1.9	22

#	ARTICLE	IF	CITATIONS
55	Concordance and Prediction Ability of Original and Reviewed Vascular Invasion and Other Prognostic Parameters of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors After Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2011, 186, 1298-1302.	0.4	21
56	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	2.6	21
57	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. <i>Journal of Urology</i> , 2018, 199, 741-747.	0.4	21
58	Penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 677-685.	1.6	20
59	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. <i>Journal of Endourology</i> , 2016, 30, 1112-1119.	2.1	20
60	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. <i>Tumori</i> , 2017, 103, 464-474.	1.1	20
61	Dexamethasone plus Ondansetron versus Dexamethasone plus Alizapride in the Prevention of Emesis Induced by Cisplatin-Containing Chemotherapies for Urological Cancers. <i>European Urology</i> , 1993, 23, 450-456.	1.9	17
62	Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis. <i>World Journal of Urology</i> , 1994, 12, 113-9.	2.2	17
63	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012, 4, 303-313.	2.0	17
64	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	1.9	17
65	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	1.2	17
66	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. <i>European Journal of Cancer</i> , 2016, 67, 91-98.	2.8	17
67	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	6.4	16
68	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	1.9	15
69	Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis in Childhood and Adolescence: An Analysis of 31 Cases. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 454-458.	0.6	14
70	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. <i>Annals of Oncology</i> , 2013, 24, 2887-2892.	1.2	14
71	In regard to Kagan: "The multidisciplinary clinic" (<i>Int J Radiat Oncol Biol Phys</i> 2005;61:967-968). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 309-310.	0.8	13
72	IGG* Practice Guidelines on Germ Cell Tumor in Adult Male Patients. <i>Tumori</i> , 2008, 94, 96-109.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	1.6	12
74	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	1.9	12
75	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	6.4	12
76	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512.	2.2	12
77	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e403-e410.	1.9	11
78	Survival analyses of adjuvant or neoadjuvant combination of a taxane plus cisplatin and 5-fluorouracil (T-PF) in patients with bulky nodal metastases from squamous cell carcinoma of the penis (PSCC): Results of a single high-volume center.. <i>Journal of Clinical Oncology</i> , 2014, 32, 377-377.	1.6	11
79	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. <i>BJU International</i> , 2011, 108, 223-227.	2.5	10
80	Estimates of prostate cancer burden in Italy. <i>Cancer Epidemiology</i> , 2016, 40, 166-172.	1.9	10
81	Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status. <i>PLoS ONE</i> , 2014, 9, e86659.	2.5	10
82	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	1.9	9
83	New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. <i>BJU International</i> , 2010, 106, 168-179.	2.5	8
84	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e1-8.e8.	1.6	8
85	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. <i>World Journal of Urology</i> , 2023, 41, 619-625.	2.2	8
86	CT-guided percutaneous cryoablation of renal masses in selected patients. <i>Radiologia Medica</i> , 2012, 117, 593-605.	7.7	7
87	Has Dynamic Sentinel Node Biopsy Achieved Its Top Performance in Penile Cancer? What Clinicians Still Need to Manage Lymph Nodes in Early Stage Penile Cancer. <i>European Urology</i> , 2013, 63, 664-666.	1.9	7
88	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e483-e487.	1.9	7
89	Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?. <i>Frontiers in Psychology</i> , 2020, 11, 576459.	2.1	7
90	Thyroid as a Target of Metastases: A Case of Metastatic Seminoma in a Patient who Died of a Second Cancer. <i>Tumori</i> , 2009, 95, 91-93.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Quality of Life and Pain Control following Laparoscopic Retroperitoneal Lymph Node Dissection in Early-stage Nonseminoma. <i>Tumori</i> , 2015, 101, 650-656.	1.1	6
92	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	1.9	6
93	Andrological complications following retroperitoneal lymph node dissection for testicular cancer. <i>Minerva Urology and Nephrology</i> , 2017, 69, 209-219.	2.5	6
94	The Role of Adjuvant Treatment in Low-Stage Germ Cell Testicular Tumors. <i>European Urology</i> , 1995, 28, 267-272.	1.9	5
95	Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?. <i>Annals of Oncology</i> , 2008, 19, 1509.	1.2	5
96	Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. <i>Tumori</i> , 2018, 104, 172-178.	1.1	5
97	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 154-164.	4.4	5
98	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 376-376.	1.6	5
99	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	1.9	4
100	The role of surgery in metastatic squamous cell carcinoma of the penis. <i>Current Opinion in Urology</i> , 2016, 26, 596-601.	1.8	4
101	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemo-resistant Germ Cell Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 60-65.	1.3	4
102	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. <i>European Journal of Surgical Oncology</i> , 2019, 45, 60-66.	1.0	4
103	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	1.9	3
104	Corrigendum to "Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe" [Eur. J. Cancer 48 (2) (2012) 159-169]. <i>European Journal of Cancer</i> , 2013, 49, 766.	2.8	2
105	Frozen Section in Testicular Pathology. , 2016, , 203-212.		2
106	Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. <i>Tumori</i> , 2018, 104, 388-393.	1.1	2
107	Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions. <i>Hereditary Cancer in Clinical Practice</i> , 2007, 5, 53.	1.5	1
108	Re: Peter Albers. Management of Stage I Testis Cancer. <i>Eur Urol</i> 2007;51:34-44. <i>European Urology</i> , 2007, 52, 295-296.	1.9	1

#	ARTICLE	IF	CITATIONS
109	Re: Roisin M. Connolly, John A. McCaffrey. High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review. <i>Eur Urol</i> 2009;56:57â€“64. <i>European Urology</i> , 2010, 57, e5-e6.	1.9	1
110	Reply to Ilker Akyol, Hasan Soydan, and Ferhat Atesâ€™ Letter to the Editor re: Nicola Nicolai, Rosalba Miceli, Andrea Necchi, et al. Retroperitoneal Lymph Node Dissection With No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>Eur Urol</i> 2010;58:912â€“8. <i>European Urology</i> , 2011, 59, e21-e22.	1.9	1
111	709 POSITIVE NODE RATIO AND TOTAL NUMBER OF POSITIVE NODES MAY PREDICT RECURRENCE IN EARLY STAGE NON-SEMINOMATOUS GERM-CELL TUMOURS UNDERGOING PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION. <i>Journal of Urology</i> , 2013, 189, .	0.4	1
112	Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. <i>Tumori</i> , 2017, 103, 292-298.	1.1	1
113	How to implement the requirements of a quality assurance system for prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 41-47.	2.2	1
114	Surgery in Non-Seminomatous Germ Cell Tumours of the Testis. , 1994, , 311-317.		1
115	Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. <i>Tumori</i> , 2013, 99, e203-7.	1.1	1
116	Rebuttal from Authors re: Oliver W. Hakenberg. A New Neoadjuvant Chemotherapy Regimen for Penile Cancer with Nodal Metastases: A Step Forward. <i>Eur Urol</i> 2009;55:552â€“3. <i>European Urology</i> , 2009, 55, 554-555.	1.9	0
117	Understanding the somatic-type malignant differentiation in male germ-cell cancer: A work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: A chemoresistant phenotype. <i>Urol Oncol</i> 2008;26:595â€“9. <i>Urologic Oncology: Seminars and Original Investigations</i> . 2009, 27, 218.	1.6	0
118	Prognostic and Predictive Factors in Pathology of the Testis. , 2016, , 159-164.		0
119	Personalise Medicine, Do Not Medicalise Persons. <i>European Urology</i> , 2017, 71, 128-129.	1.9	0
120	Is There Still an Indication for Primary RPLND in Clinical Stage I Non-seminoma?. , 2015, , 29-54.		0
121	New Landmarks Towards Reducing the Treatment Burden for Patients with a Postchemotherapy Residual Retroperitoneal Mass from Nonseminomatous Germ-cell Testicular Tumors. <i>European Urology Oncology</i> , 2022, , .	5.4	0
122	Total embedding of spermatic cord and hilar soft tissue in orchiectomy for seminoma: does the extensive sampling improve pathologic risk factors?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	2.8	0